| scholarly article | Q13442814 |
| P50 | author | Catherine S Adamson | Q55364196 |
| Nicholas J Westwood | Q58183835 | ||
| P2093 | author name string | Terry K Smith | |
| Lisa Pirrie | |||
| Fanny Tran | |||
| Christopher Murgatroyd | |||
| P2860 | cites work | The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles | Q21245046 |
| A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat | Q24606079 | ||
| Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection | Q24672964 | ||
| Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors | Q27324263 | ||
| Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution | Q27617655 | ||
| Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly | Q27683857 | ||
| Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution | Q27696126 | ||
| Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein | Q27746461 | ||
| Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation | Q28360742 | ||
| Structural and functional insights into the HIV-1 maturation inhibitor binding pocket | Q28485054 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Assembly and architecture of HIV. | Q30455050 | ||
| Retroviral proteases and their roles in virion maturation | Q38393674 | ||
| HIV-1 assembly, release and maturation. | Q38539565 | ||
| HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. | Q38549717 | ||
| Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 | ||
| Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. | Q39685850 | ||
| A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1. | Q39699793 | ||
| Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein | Q39748566 | ||
| The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity | Q39870242 | ||
| Methods for the study of HIV-1 assembly. | Q39914278 | ||
| The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. | Q40042979 | ||
| Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein | Q40059062 | ||
| Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. | Q40131039 | ||
| Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles | Q40357793 | ||
| Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat | Q40750425 | ||
| Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. | Q40894533 | ||
| Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process | Q41844750 | ||
| Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 | Q42202820 | ||
| 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro | Q42424208 | ||
| A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | Q42546287 | ||
| Flexibility in the P2 domain of the HIV-1 Gag polyprotein | Q43094794 | ||
| Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy | Q45760702 | ||
| Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease | Q69564852 | ||
| Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag | Q30478394 | ||
| Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells | Q30479297 | ||
| Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease | Q30850215 | ||
| Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging | Q30980940 | ||
| Novel approaches to inhibiting HIV-1 replication. | Q33624690 | ||
| The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation | Q33727091 | ||
| A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly | Q33782377 | ||
| Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle | Q33782781 | ||
| Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding | Q33787084 | ||
| Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly | Q33794223 | ||
| Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors | Q33814879 | ||
| Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat | Q33864444 | ||
| On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch? | Q34164929 | ||
| HIV chemotherapy | Q34223088 | ||
| p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease | Q34288376 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice | Q34529834 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). | Q35139703 | ||
| Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice. | Q35832693 | ||
| Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants | Q36185528 | ||
| Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. | Q36340098 | ||
| Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. | Q36624411 | ||
| Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. | Q36632356 | ||
| Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. | Q36650046 | ||
| New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. | Q36691642 | ||
| Human immunodeficiency virus type 1 assembly, release, and maturation. | Q36857103 | ||
| The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors | Q36881276 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation | Q36944553 | ||
| PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | Q37089562 | ||
| Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) | Q37192174 | ||
| A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition. | Q37336728 | ||
| New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation | Q37450688 | ||
| HIV-1 assembly, budding, and maturation | Q38023864 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8181-8197 | |
| P577 | publication date | 2016-09-15 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 | |
| P478 | volume | 90 |
Search more.